Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Retained Earnings (2016 - 2025)

Ligand Pharmaceuticals' Retained Earnings history spans 16 years, with the latest figure at $8.5 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 98.31% year-over-year to $8.5 million; the TTM value through Dec 2025 reached $8.5 million, down 98.31%, while the annual FY2025 figure was $8.5 million, 98.31% down from the prior year.
  • Retained Earnings for Q4 2025 was $8.5 million at Ligand Pharmaceuticals, down from $9.3 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $530.1 million in Q3 2024 and bottomed at -$1.6 million in Q1 2025.
  • The 5-year median for Retained Earnings is $8.5 million (2025), against an average of $193.7 million.
  • The largest annual shift saw Retained Earnings tumbled 100.23% in 2021 before it skyrocketed 54448.78% in 2022.
  • A 5-year view of Retained Earnings shows it stood at -$917000.0 in 2021, then fell by 7.31% to -$984000.0 in 2022, then skyrocketed by 51219.51% to $503.0 million in 2023, then fell by 0.8% to $499.0 million in 2024, then tumbled by 98.31% to $8.5 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Retained Earnings are $8.5 million (Q4 2025), $9.3 million (Q3 2025), and $8.5 million (Q2 2025).